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In Algeria, Leishmania infantum, Leishmania major, and Leishmania killicki (Leishmania tropica) are responsible for cutaneous
leishmaniosis. We established a murine model of L. killicki infection to investigate its infective capacity, some immunophys-
iopathological aspects, and its suitability for pharmacological purposes. Following the injection of L. major or L. killickimetacyclic
promastigotes in the ear dermis of BALB/c mice, the course of infection was followed. The infection with L. killicki caused slower
lesion formation than with L. major. The presence of L. killicki or L. major DNA and parasites was detected in the ear dermis and in
lymph nodes, spleen, and liver. Lesions induced by L. killicki were nonulcerative in their aspect, whereas those caused by L. major
were highly ulcerative and necrotic, which matches well with the lesion phenotype reported in humans for L. killicki and L. major,
respectively. The treatment of L. killicki lesions by injection of Glucantime® significantly reduced the lesion thickness and parasite
burden. Ear dermal injection of BALB/cmice constitutes amodel to study lesions physiopathology caused by L. killicki and presents
interest for in vivo screening of new compounds against this pathogen, emerging in Algeria.
1. Introduction
Leishmania are obligate intracellular parasites, which cause
different forms of leishmanioses in humans, ranging from
dermal ulcers to fatal visceral forms. Cutaneous leishman-
ioses (CL) are caused by several Leishmania species and
display various clinical manifestations. In Algeria, L. killicki
was discovered in 2005 in the southern province of Ghardaia
and recently reported in the northern part of the country
[1, 2]. Phylogenetic studies based on Multilocus Enzyme
Electrophoresis showed that L. killicki strains were included
in clearly distinct clades within the L. tropica complex. A
recent Multilocus Sequence Analysis further evidenced the
substructuration of L. tropica species and supported this
proposal [3, 4]. In Algeria, up till now only strains belonging
to the L. killicki subgroup within the L. tropica complex have
been isolated. The pathogenicity and the infectivity of these
strains have never been studied. Cutaneous lesions caused
Hindawi Publishing Corporation
BioMed Research International
Volume 2016, Article ID 7985104, 8 pages
http://dx.doi.org/10.1155/2016/7985104
2 BioMed Research International
by L. tropica tend to form dry ulcers that require a long
time to heal, typically one year or more. Healing is often
associated with disfiguring scars and papules that can also
recur at the periphery of the original lesion and are called
recurrent type lesions [5, 6]. Cutaneous lesions caused by
L. killicki are called chronic cutaneous lesions because they
persist for several years [7]. So clinical signs of cutaneous
leishmaniosis due to L. killicki are restricted to a chronic
cutaneous lesion, resistant to standard treatment in opposite
to L. tropica cutaneous leishmaniosis [8–11]. In addition, the
transmission of L. killicki seems to be strictly zoonotic, while
it is anthroponotic or occasionally anthropozoonotic for L.
tropica.
Animal models have been used in the drug discovery and
development process to characterize disease physiopathology
and to estimate clinical dosing regimens safety margins and
toxicity and of course to validate targets and compounds.
The ideal in an animal model is that it should replicate to a
great extent a human disease phenotype and its underlying
causality. Many experimental models have been developed
on rodents to study CL. Mouse models were established
for L. major, L. tropica, L. amazonensis, and L. braziliensis,
each with specific features in order to characterize the
immune response, but none of them reproduces the pathol-
ogy observed in human disease [12–14]. For L. tropica and L.
major, patterns of responses are species specific with different
sex effects and largely different host susceptibility genes [6, 15,
16]. So, L. killicki causes in humans cutaneous lesions, which
tend to form dry ulcers similar in their aspect to those caused
by L. tropica [1, 6, 7]. Nevertheless, their healing requires a
longer period of treatment. CL caused by L. killicki is called
chronic CL because lesions persist for years, as opposed to
CL caused by L. major for which lesions usually resolve with
scare after few months only [7].
The aims of this work were therefore to develop an animal
model that allows us to study basic physiopathological and
immunological aspects of the infection caused by L. killicki
and to evaluate its suitability for pharmacological purposes.
2. Materials and Methods
2.1. Parasites. L. major (MHOM/DZ/10/LIPA175/11) and
L. killicki (MHOM/DZ/11/LIPA281/11) were maintained in
RPMI 1640medium supplementedwith 10% heat-inactivated
FBS, 2mM L-glutamine, 25mM glucose, 100 𝜇g/mL strepto-
mycin, and 100 IU/mL penicillin at 25∘C. Strain virulence was
maintained by a regular passage in susceptible BALB/c mice.
2.2. Ethics Statement. All experiments were carried out in
compliance with the guidelines of the Federation of Euro-
pean LaboratoryAnimal ScienceAssociations (FELASA) and
approved by the Ethical Committee of the Pasteur Institute in
Algiers.
2.3. Mouse Infection. A total of 120 BALB/c mice were
obtained from the animal breeding stock facility of Pasteur
Institute in Algiers. Six-week-old females were kept in con-
ventional conditions with barriers, controlled temperature,
and light cycle. Food and water were provided ad libitum.
Infective promastigotes were isolated at the metacyclic stage
from stationary phase cultures (6 days old). Metacyclic
promastigotes were isolated on a Ficoll gradient [17], washed
once with phosphate buffered saline (PBS) (pH 7.3), and then
resuspended in PBS (pH 7.3). 103metacyclic promastigotes in
10 𝜇L of PBS were injected in the left ear of each mouse [13].
2.4. L. killicki Animal Model. To establish an in vivo model
of cutaneous lesions caused by L. killicki, we compared
the appearance and the induration thickness of the lesion
following intradermal inoculation with L. killicki or L. major
into the ear dermis of BALB/c mice. To monitor lesion
development, mice were divided into three groups: 5 mice
for the control noninfected mice, 5 mice infected with L.
major, and 5 mice infected with L. killicki. Experiments
were conducted during 12 consecutive weeks after infection
in mice infected with L. major and during 30 consecutive
weeks after infection for mice infected with L. killicki. Lesion
development was monitored by measuring the ear thickness
using a digital micrometer caliper (Fisherbrand) at weeks 2,
4, 6, 10, and 12 after infection for L. major and at weeks 2, 4,
6, 8, 10, 12, 14, 16, 18, 20, and 30 after infection for L. killicki.
Results are expressed as the difference between thicknesses
of the inoculated ear and the noninoculated contralateral ear
(internal control).
2.5. Detection and Quantification of Parasites in Tissues. To
look at the capacity of L. killicki and of L.major to disseminate
into internal organ, the presence of parasite DNA and of
live parasites was investigated at weeks 2, 4, 8, and 12 for
L. major infected mice and at weeks 2, 4, 8, 12, 16, and
20 for the L. killicki group. Mice were euthanized, and the
retromaxillary draining lymph nodes, spleen, and liver were
collected to extract DNA. At the 12th week, an aliquot from
each sample was seeded to LIT (Liver Infusion Tryptose)
medium and incubated for 4 weeks in order to isolate
live parasites. Samples of tissue were homogenized in PBS
using potter grinders and 1.5mL microtubes with single-
use blue pellet pestles (Polylabo, France). Homogenates were
then aliquoted and stored at −20∘C until DNA extraction.
Total DNA was purified using the QIAamp DNA mini kit
(QIAGEN) according to themanufacturer’s protocol. Parasite
DNA was detected after amplification of the ribosomal
internal transcribed spacer 1 (ITS1) using primers LITSR and
L5.8S previously designed by Scho¨nian et al. [18]. The PCR
mix (25 𝜇L) contained 2.5 𝜇L of DNA, 10x buffer, 300 𝜇M
MgCl
2
, 200𝜇MdNTP, 500 nM of each primer, and 2U of Taq
DNA polymerase. Amplification products were separated on
a 1% agarose gel and visualized after staining with ethidium
bromide.
To investigate parasite proliferation during lesion expan-
sion, we measured the parasite load at the inoculation site.
At weeks 4, 8, and 12 for L. major infected mice and at
weeks 4, 8, 12, 16, 20, and 30 for L. killicki groups, mice
were euthanized. Parasite proliferation within the lesion was
monitored by counting the number of amastigotes inGiemsa-
stained smears under 100x magnification. The number of
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Figure 1: Clinical evolution of the ear lesions in BALB/c mice. Lesions’ appearance in mice infected with L. major (4th week after infection)
(a) or L. killicki (20th week after infection) (b).
infected macrophages and the mean number of amastigotes
per macrophage were determined in one hundred randomly
selected fields. The results are expressed as the mean number
of parasites per 100 macrophages.
2.6. Drug Treatment. In a first attempt to investigate the
capacity of this new in vivo murine model of infection with
L. killicki to be used for the screening of new antileishma-
nial compounds, we compared the outcome of Glucantime
treatment which consisted in injecting drug into lesions at
weeks 4 and 8 for L. major and L. killicki, respectively. In all
experiments, the treatment was initiated when the infection
was well established and when the lesions were obvious 4 and
8 weeks after the inoculation with L. major and L. killicki,
respectively. Two days before drug administration, mice
were randomly divided into 2 groups of thirty animals. N-
Methylglucamine antimoniate (pentavalent antimony: SbV)
was diluted in PBS and then administered tomice by injection
directly into lesions at a dose of 28mg per kg of body weight
every 5 days for 15 days. Ear thickness was measured weekly
during the treatment and after the end of the treatment. The
antimony treatment efficiency was monitored by calculating
ear thickness and parasite load indexes:
Ear thickness index = mean thickness of ear from
treated mice/mean thickness of ear from untreated
mice.
Parasite load index = mean parasite load in untreated
mice/mean parasite load in treated mice.
2.7. Statistical Analysis. Values are given as the mean ± SEM
for groups of 𝑛 samples. Analysis of variance (ANOVA)
and Student’s 𝑡-test were performed using GraphPad Prism
Software (GraphPad Software Inc., San Diego, California,
USA) and Microsoft Office Excel 2013 was used to determine
the significance of differences.
3. Results
3.1. Lesion Appearance and Development. A striking dif-
ference in the onset, the type, and the severity of lesions
was observed between both Leishmania species. Cutaneous
redness, which is the first symptom of infection caused
by tissue inflammation, was detectable 2 weeks after the
infection of mice with L. major but 4 weeks after infection
with L. killicki.
After 4 weeks, L. major-infected mice exhibited lesions
with elevated borders and sharp craters (Figure 1(a)). Mice
infected with L. killicki developed a detectable lesion later: the
ear thickness increased progressively during the time course
of the experiment (Figure 1(b)). Infection never caused lesion
ulceration, which was observed in L. major-infected mice.
Strikingly, lesion phenotypes induced by L. killicki were
clearly distinct from those induced by L. major.
In mice infected by L. major metacyclic promastigotes,
thickening of the ear was observed at the inoculation site
as early as 3 weeks after infection. The ear thickness rapidly
increased, reached a maximum of 2.4mm at week 10, and
then regressed (Figure 2). For L. killicki, the ear thickness
expanded linearly and more slowly throughout the time
course of the experiment to reach 1.4mm and 4.3mm at
weeks 10 and 30, respectively.
3.2. Parasite Burden in the Ear Dermis and Occurrence in
Other Organs or Tissues. The presence of parasites in the ear
dermis ofmice inoculatedwith L.majorwas observed as early
as the 4th week (Figure 3). Moreover, the parasite burden
steadily increased until the 8th week and the maximum was
reached at the 10th week (Figures 1 and 3). As from this time,
the ear thickness and the lesion size slightly decreased until
the ear perforated.
The onset of parasite burden in L. killicki-infected mice
was different. Parasite expansion began later than for L.
major, 8 weeks after infection, reached its maximum at week
16, and was maintained until the end of the experiment
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Figure 2: Evolution of indurations following infection of BALB/c
mice with Leishmania killicki or Leishmaniamajor.Theear thickness
is expressed as the difference between the thicknesses of the
inoculated ear and the noninoculated contralateral ear. The data
represent themean values ofmeasures± standard deviations (𝑛 = 5).
Note: 12weeks (∗) after infectionwithL.major, ears becamenecrotic
and showed a loss of tissue which has prompted us to interrupt the
experiment at this time.
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Figure 3: Parasite burden measured in ears of BALB/c mice
infected with Leishmania killicki or Leishmania major. Following
intradermal injection of 103 metacyclic promastigotes, the parasite
load was estimated as described in Materials and Methods. Each
bar is representative of the mean of five determinations ± standard
deviations. Statistical analysis (∗𝑝 < 0.05 and ∗∗𝑝 < 0.01) was
performed using Student’s 𝑡-test under GraphPad Prism (𝑛 = 5
mice/group).
at week 30. The maximal parasite burden was significantly
higher than for L. major-infected mice (𝑝 < 0.001). In
L. killicki-infected mice, no further parasite expansion was
observed after the 12th week, while the induration thickness
increased (Figures 1 and 3).
Beyond the capacity of Leishmania to replicate at the
inoculation site, the dissemination of L. killicki and L. major
in various tissues or organs was further investigated (Table 1).
L. major and L. killicki were both detected in culture at 12
weeks. Indeed, DNA detection evidenced the presence of
parasites at the inoculation site from the 2nd week after
infection for both species. However, the major difference
was the delay observed for the colonization of the organ
following infection. L.major colonized draining lymph nodes
and spleen more quickly, 2 weeks after infection compared to
4 weeks for L. killicki (Table 1). DNA was detected in liver 4
weeks after infection for both species. After this time point,
the PCR remained positive until the 12th week for L. major
and the 20th week for L. killicki.
3.3. Compared Clinical Evolution of L. killicki and L. major
Lesions and Parasite Load under Antimonial Treatment. The
ear thickness was roughly similar in L. major-infected mice
when treatedwith drug or PBS (Figure 4(a)).The reduction in
the lesions observed in L. major-infected mice 10 weeks after
infection was due to tissue necrosis and loss. These results
show that antimony has no or undetectable effect on L. major
lesions after the end of the treatment, although at concentra-
tion we used in our experiment (Figure 4(c)). Interestingly,
the expansion of lesion halted in treated L. killicki-infected
mice submitted to chemotherapy (Figure 4(b)). Accordingly,
the ear thickness index increased constantly during the time
course of the treatment (Figure 4(c)).
Glucantime treatment slightly affects the parasite load
with only 0.12-fold reduction of themean number of L. major
amastigotes/100 macrophages in lesions (see Figures 5(a) and
5(c)). However, it is more efficient in L. killicki-infected mice,
which exhibited twofold reduction in L. killicki amastigotes
(Figures 5(b) and 5(c)). Parasite loads were significantly
different as early as one week after the beginning of the
treatment, that is, at the third injection of Glucantime (𝑝 <
0.001). Overall, a better concordance between parasite load
and ear thickness was observed in mice infected with L.
killicki during antimony treatment than inmice infected with
L. major.
4. Discussion
In this work we seek for the first time to establish a CL animal
model for the emerging Leishmania parasite in Algeria: L.
killicki. In an attempt to reproduce the natural biology of
Leishmania transmission, Belkaid et al. [19] established a
dermal model of infection in which low numbers of L.
major promastigotes were injected into the ear. Based on this
methodology, we established a dermal model of infection
using L. killicki, which involved a cutaneous lesion in the
ear dermis of mice, similar to those observed in patients
with L. killicki infection, that is, localized lesions that do not
heal spontaneously. The appearance of lesions induced by L.
killicki is different from those produced by L. major or L.
tropica sensu stricto [6, 16]. Experimental infection of BALB/c
mice with L. tropica produced lesions that developed up to
3 months after infection and then regressed [6, 16]. In mice
infected with L. killicki, we never observed regression of the
ear thickness but a continuous extension of the lesion. Indeed,
in humans, L. killicki induces chronic lesions that persist up
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Table 1: Detection of L.major and L. killicki DNA and parasitesin various tissues of BALB/c mice. ND, not determined.
Leishmania Tissue or organ PCR after inoculation/LIT culture
2 weeks 4 weeks 8 weeks 12 weeks 16 weeks 20 weeks
L. major
Ear (inoculation site) + + + +/ND
Draining lymph node + + + +/+
Spleen + + + +/+
Liver − + + +/+
L. killicki
Ear (inoculation site) + + + +/ND + +
Draining lymph node − + + +/+ + +
Spleen − + + +/+ + +
Liver − + + +/+ ND ND
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Figure 4: Effect of Glucantime treatment on ear induration in mice infected with Leishmania major (a) or Leishmania killicki (b) and on
the ear thickness index (c). Grey bars indicate the Glucantime treatment period. The induration thickness is expressed as the difference of
thicknesses between infected ears and contralateral noninoculated ear (control). Data are expressed as mean values ± standard deviations
(error bars) (𝑛 = 5).
to one year [2]. In the mouse, we observed that L. killicki
lesions do not spontaneously heal but persist and develop
all along the experiment. Further studies will be required
to understand the underlying immunological determinants
allowing the long-term persistence of L. killicki in lesions. In
the old world, only L. infantum and L. donovani are known
to cause visceral forms of leishmaniosis (VL). Nevertheless,
these two species can also be the causative agents of some
forms of CL [20, 21]. In the same way, L. tropica as L.
major cause CL in humans but different studies reported
the isolation and characterization of L. tropica in patients
with VL [8, 22–24]. In mice, L. tropica or L. major are also
known to cause visceral infections; that is, they are detected in
spleen and liver but the rapidity of the visceral dissemination,
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Figure 5: Parasite load inmice infected with Leishmaniamajor (a) or Leishmania killicki (b) and evolution of the parasite load index following
antimony treatment (c).The parasite load index was calculated as follows: mean parasite load in untreated mice/mean parasite load in treated
mice. Each bar is representative of the mean parasite load determined in 5 mice ± standard deviations (error bars). Statistical analysis (∗∗∗𝑝 <
0.01) was performed using Student’s 𝑡-test under GraphPad Prism (𝑛 = 5mice/group). Grey bar indicates the Glucantime treatment period.
the symptoms observed, and the parasite load differ between
L. tropica and L. major [25–27]. We observed that L. killicki
had also the capacity to disseminate and to persist in internal
organs of mice. Nevertheless, the ability of L. killicki to cause
VL in humans remains unknown and has not been reported
to date.
L. killicki is considered as an emerging pathogen resistant
to pentavalent antimonial treatment [1, 2, 7, 10]. Therefore,
it would be interesting to evaluate the suitability of this
L. killicki infection model in experimental pharmacology.
This infection model could test the leishmanicidal activity
of known drugs and be predictive of their clinical efficacy.
Currently, animal models of infection optimized to test
antileishmanial compounds are available for L. major and L.
amazonensis [28, 29]. Human infections caused by L. tropica
complex are considered to be refractory to most classical
treatments, including antimonial containing drugs, unlike L.
major infections [22, 30, 31]. In our study, we have observed
that antimony treatment does not affect the outcome of
lesions induced by L. major in contrast to L. killicki. In fact,
the outcome of the experiment cannot be further followed
in mice infected with L. major because of lesions’ necrosis.
The treatment of mice infected with L. killicki resulted in the
reduction of lesions size and of the thickness which were
associated with a drastic diminution of the parasite load at
the inoculation site.
5. Conclusions
Our observations support the notion that this L. killicki
model of infection has several practical advantages over the
L. major model. First, the drug regimen can be evaluated
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over a longer time period (up to 30 weeks) as compared to
L. major, where tissue loss and the appearance of ulcerative
lesions limit the time course of the experimentation. Second,
the intense and continuous parasite multiplication at the
inoculation site makes it possible to more easily assess
the leishmanicidal activity of new molecules in a simple
way. The continuous emergence of antimony resistance in
Leishmania spp. in various parts of the world necessitates the
development of new alternative antileishmanial drugs [32–
34]. To this end, this study supports the notion that this new
L. killicki experimental model might be useful for screening
and validating new compounds in vivo.
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